MOBERG DERMA YEAR-END REPORT 2012

DOUBLED REVENUE, PROFITABLE AND ESTABLISHMENT IN THE U.S.
FULL-YEAR (JAN-DEC 2012)

  · Revenue MSEK 112.5 (55.9)
  · Operating profit MSEK 12.6 (-7.6), MSEK 19.2 excluding acquisition-related
costs
  · Net profit after tax MSEK 35.8 (-6.4), MSEK 42.4 excluding acquisition
-related costs
  · Earnings per share SEK 3.68 (-0.82)
  · Operating cash flow per share SEK 0.97 (-0.99)
  · The Board proposes no dividend for the 2012 fiscal year

FOURTH QUARTER (OCT-DEC 2012)

  · Revenue MSEK 30.2 (20.5)
  · Operating profit/loss MSEK -0.7 (3.8); MSEK 5.9 excluding acquisition
-related costs
  · Net profit/loss after tax MSEK -6.3 (4.4); MSEK 0.3 excluding acquisition
-related costs
  · Earnings/Loss per share SEK -0.63 (0.48)
  · Operating cash flow per share SEK -0.26 (1.84)

SIGNIFICANT EVENTS DURING THE FOURTH QUARTER

  · Proprietary market presence in the U.S. established through the acquisition
of Alterna LLC. In conjunction with the acquisition, an issue in kind of 825,652
shares and loan financing of MSEK 40.0 where effected.
  · Through a private placement, Moberg Derma raised MSEK 31.8 before issue
expenses.
  · George Aitken-Davies, Management Director of Altaris Capital Partners, was
elected a new Board member.
  · New Phase II study initiated of MOB-015 for the treatment of onychomycosis.
  · Distribution agreement entered into with Paladin Labs Inc. for
Nalox™/Emtrix® in Canada.

CEO COMMENTARY
The key factor that enabled us to double our revenue in 2012 and achieve
profitability one year ahead of expectations was the successful
commercialization of Nalox™. During the autumn, we took the next step in our
growth strategy – establishment in the U.S. The acquisition of Alterna has
equipped us with our own sales organization in the world’s largest
pharmaceutical market and broadened our portfolio with established brands,
including the rights to Kerasal Nail™ (Nalox™ in Sweden).

The rapid increase in revenue resulted from the successful progress made this
year for the global commercialization of Nalox™, which is now sold in 20
countries. Nalox™ retains its position as the market leader in the Nordic
region, where the total market for the treatment of nail fungus has expanded
significantly as a result of our launch. We worked intensively during the year
to support our partners and distributors in conjunction with the launches in 12
markets, which included France, Germany, the Netherlands, Italy, Austria and
South Africa. The product has also quickly become one of the leaders in several
of these new markets. New agreements were signed with selected distributors in
Canada, South Africa and Iran, and all remaining milestone payments were
received from Meda.

In the U.S., Kerasal Nail™ was ranked number two in its category in U.S.
drugstores. This is the result of a targeted launch in the U.S., where we
successfully expanded distribution to more than 25,000 retail stores, including
nearly all of the Walmart stores. Furthermore, Kerasal Nail™ was nominated to
the Drug Store News’ Top-50 list of the Most Innovative New Products in
competition with thousands of products.

The integration of our acquired U.S. unit is proceeding as planned. An
integrated organization is in place and the company was recently renamed Moberg
Pharma North America LLC. The U.S. operation performed strongly in the fourth
quarter, of which about one month is included in our accounts for 2012.

One of the accounting effects of the acquisition is a revaluation up to its fair
value of the inventory held by the U.S. firm in the amount of MSEK 4.6, thus
reducing earnings by a corresponding amount. A positive effect is that
acquisition values of MUSD 17.9 will be eligible for tax write-offs in the U.S.
for a period of 15 years.

We focus continuously on new ideas and products through internal development and
evaluation of acquisition candidates. The aim is to meet the needs of patients
for new treatments in commercially attractive niche markets. At present, we have
two internally development projects in clinical phases: MOB-015 for the
treatment of nail fungus and Limtop for the treatment of actinic keratosis (sun
-damaged skin). A Phase II study of an improved formulation of MOB-015 was
initiated in December and, for the Limtop project, Phase II data is expected in
the first six months of 2013.

As a result of the acquisition of Alterna, we had the pleasure of welcoming new
shareholders to the company bringing extensive experience and international
networks: The Third Swedish National Pension Fund, Handelsbanken Funds and
Rhenman & Partners, as well as the U.S. private equity fund Altaris Capital
Partners.

Our shareholders can look back on a successful year. The progress in 2012 has
made us a substantially stronger and profitable company, with favorable
prospects for continued strong growth in 2013.

Peter Wolpert, CEO

TELEPHONE CONFERENCE
CEO Peter Wolpert will present the report in a telephone conference today at
10:30 a.m. (CET), February 5, 2013. Telephone: +46 (0)8-506 26 900 and submit
the code 409017

ABOUT THIS INFORMATION
Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 8:30 am (CET) on February 5th,
2013.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Peter Wolpert, President and CEO of Moberg Derma
Mobile: +46 70-735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se
For further information about Moberg Derma, please visit: www.mobergderma.com